KA27 001
Alternative Names: anti-CD27 agonist mAb - Kineta; anti-CD27 mAbs - Kineta; anti-CD27 monoclonal antibodies - Kineta; Anti-CD27 monoclonal antibody - Kineta; KA27-001; αCD27 mAbs; αCD27 monoclonal antibodies - KinetaLatest Information Update: 09 May 2024
At a glance
- Originator GigaGen
- Developer Kineta
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- Discontinued Haematological malignancies